Navigation Links
Vermillion Announces Return of Eric Fung, M.D., Ph.D.

FREMONT, Calif., Oct. 2 /PRNewswire-FirstCall/ -- Vermillion, Inc (OTC: VRMLQ.PK) today announced that Eric Fung, M.D., Ph.D., has rejoined the company to become its Chief Science Officer. This position will be formally held by Dr. Fung upon the completion of the Company's restructuring and reorganization under Chapter 11 of the U.S. Bankruptcy Code or earlier, if deemed appropriate by Vermillion's Board of Directors. In the interim, Dr. Fung will work as an independent consultant.

"Dr. Fung was instrumental in the development of the OVA1(TM) test, including biomarker discovery to validation, design and execution of the clinical trial, and submission to the FDA," said Gail Page, Executive Director of the Company. "We are pleased to welcome him back to Vermillion, where he will play a key role in commercialization of the OVA1 test as well as further development of other potential tests in Vermillion's pipeline."

Dr. Fung, age 39, is returning to the company after serving as Director of Clinical Research at Roche Molecular Systems. At Roche, he helped oversee a cervical cancer screening clinical trial involving 45,000 women. Dr. Fung originally joined Vermillion in May 2000 as a lead scientist in the newly formed Biomarker Discovery Centers. He was promoted to Vice President and Chief Scientific Officer in June 2006.

Prior to joining Vermillion, Dr. Fung was a Howard Hughes sponsored researcher at Stanford University. Dr. Fung has anatomic pathology training from Stanford Medical School and obtained his M.D. and Ph.D. degrees from the Johns Hopkins University School of Medicine. He graduated with a B.S. with honors from the California Institute of Technology. Dr. Fung has also held an Adjunct Assistant Professor position in the Department of Pathology at the Johns Hopkins University School of Medicine.

About the OVA1 Test

The OVA1 Test is a qualitative serum test that combines the results of five immunoassays into a single numerical score. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. The test utilizes five well-established biomarkers --- Transthyretin (TT or prealbumin), Apolipoprotein A-1 (Apo A-1), Beta2-Microglobulin (Beta2M), Transferrin (Tfr) and Cancer Antigen 125 (CA 125 II) -- and a proprietary algorithm to determine the likelihood of malignancy in women with pelvic mass for whom surgery is planned.

The OVA1 Test is an aid to further assess the likelihood that malignancy is present when the physician's independent clinical and radiological evaluation does not indicate malignancy. The test should not be used without an independent clinical/radiological evaluation and is not intended to be a screening test or to determine whether a patient should proceed to surgery. Incorrect use of the OVA1 Test carries the risk of unnecessary testing, surgery, and/or delayed diagnosis.

Quest Diagnostics, which is a long-time investor in research and development of the OVA1 technology, has exclusive rights to offer the test to the clinical reference laboratory market in the U.S. for three years.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at


    Jill Totenberg
    The Totenberg Group
    Tel:  212 994 7363

SOURCE Vermillion, Inc.

SOURCE Vermillion, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
2. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
3. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
4. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
5. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
6. Vermillion Receives NASDAQ Notice of Non-Compliance
7. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
8. Vermillion Announces Effectiveness of Reverse Stock Split
9. Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
10. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
11. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
Post Your Comments:
(Date:10/8/2015)... -- The 2015 Nobel Prize in Chemistry has been ... Aziz Sancar , who earned his PhD in molecular ... 1977, is one of three scientists who received the Nobel Prize ... DNA on a molecular level.  --> Aziz Sancar , ... Dallas in 1977, is one of three ...
(Date:10/8/2015)... , Oct. 8, 2015  Sigma-Aldrich Corporation ... Cerilliant ® brand within its Applied Diagnostics ... bile acid reference standards product line with ten ... routinely tested bile acids and their stable-labeled internal ... consist of lithocholic acid, taurocholic acid and native ...
(Date:10/7/2015)... Oct. 7, 2015 Boston Scientific ... of the Boston Scientific Connected Patient Challenge , ... the use of remote patient monitoring to enhance patient ... entrepreneurs can submit their ideas and collaborate on solutions ... ). Cambridge, MA where ...
(Date:10/7/2015)... --  PDI , a leader in infection prevention products ... challenges across various healthcare settings, as well as guidelines ... tool is part of a larger effort to raise ... and lower healthcare-associated infections. ... how to use the right product, in the right ...
Breaking Biology Technology:
... CLEARWATER, Fla., Sept. 26 Advanced Bio-Technologies,Inc (ABT) is ... have been purchased by HealthEdge Investment Partners of Tampa,FL. ... CEO, commented, "This is a new stage,in the exciting ... up,sales and marketing in the USA, build the necessary ...
... Mich., Sept. 26 MichBio, the,association for Michigan,s life ... held October 16 in East Lansing. Michigan State,University has ... event on,its campus. Career Day is intended to introduce ... educational and career opportunities in,the life sciences. It takes ...
... 26 Today the National,Collegiate Inventors and Innovators ... Biomedical Innovation, Design, and Entrepreneurship,Awards (BMEidea) program. The ... innovation teams via its online submission,system through April ... may apply,(by November 9, 2007) for a $500 ...
Cached Biology Technology:
(Date:9/24/2015)... LONDON , September 24, 2015 /PRNewswire/ ... 00.01 25 september 2015 Kerv ... inom digitala finanstjänster, lanserar idag världens första ... att samla in 77 000 GBP för ... ) , ...
(Date:9/10/2015)... Report Details The global wearable technology market ... of revenues, consumer adoption and even technological advances. However, ... begin to achieve that mass market acceptance that has ... the entrance of Apple to the SmartWatches market, which ... overall size of the wearable technology market. Visiongain ...
(Date:9/9/2015)... 2015  NuData Security announced today that it ... the company,s commitment to protecting organizations and individuals ... NuData Security,s online fraud detection solution, NuDetect, has ... The product combines continual analysis and behavioral biometrics ... from fraudulent behavior, allowing the company to detect ...
Breaking Biology News(10 mins):
... Scientists at Scripps Institution of Oceanography at UC San ... a little-known marine worm that produces a dazzling bioluminescent ... released into seawater. Found around the world in ... light produced by the Chaetopterus marine wormcommonly ...
... at the Scripps Translational Science Institute (STSI) have teamed ... Wellbeing in a novel study of the ancient practice ... from meditators. "Although the health benefits of meditation ... immediate effects of meditation on the heart and vascular ...
... Recent work from University Distinguished Professor of Biology Kim ... health threats of our time. In a groundbreaking study ... team presents a novel approach to treat and eliminate ... potent bacterium whose resistance to antibiotics has kept it ...
Cached Biology News:
... Epitope: aa 16-25 of human GSK3 ... Recommended Storage: Store vial at -20 C prior ... extended storage aliquot contents and freeze at -20 C or ... Family: Other Sub-Family: not ...
S-100 alpha/beta chain (8B10)...
... Acetate: CoA ligase (AMP forming), Acetate thiokinase ... protein content. Physical form: Lyophilized ... and reduced glutathione Preparation Unit ... of S-acetyl coenzyme A from acetate, ATP ...
SCCRO (S-17)...
Biology Products: